5-HT3 receptor antagonists: Differences and similarities
- 1 August 1997
- journal article
- review article
- Published by Elsevier in European Journal Of Cancer
- Vol. 33 (9) , 1364-1370
- https://doi.org/10.1016/s0959-8049(97)00003-8
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trialCancer, 1996
- An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimensEuropean Journal Of Cancer, 1996
- Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesisAnnals of Oncology, 1995
- Ondasetron versus granisetron in the prevention of chemotherapy-induced nausea and vomiting. Results of a prospective randomized trialCancer, 1994
- 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy—A randomised studyEuropean Journal Of Cancer, 1993
- Are all 5-HT3 receptor antagonists the same?European Journal Of Cancer, 1992
- Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesisThe Lancet, 1992
- Review paperAnti-Cancer Drugs, 1992
- Ondansetron and Tropisetron with Dexamethasone in the Prophylaxis of Acute Vomiting Induced by Non-cisplatin-Containing ChemotherapyActa Oncologica, 1992
- Emerging differences between 5-HT3 receptor antagonistsAnti-Cancer Drugs, 1991